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Abstract
Lung cancer is the leading cause of cancer deaths worldwide. If we can define and detect
preneoplastic lesions, we might have a chance of improving survival. The World Health Organization
has defined three preneoplastic lesions of the bronchial epithelium: squamous dysplasia/carcinoma in
situ; atypical adenomatous hyperplasia; and diffuse idiopathic pulmonary neuroendocrine cell
hyperplasia. These lesions are believed to progress to squamous cell carcinoma, adenocarcinoma and
carcinoid tumors, respectively. In this review we summarize the data supporting the preneoplastic
nature of these lesions, and delve into some of the genetic changes found in atypical adenomatous
hyperplasia and squamous dysplasia/carcinoma in situ.
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Introduction
Lung cancer is the leading cause of cancer deaths world-
wide [1] and the number of cases continues to increase.
Smoking is the primary cause in the great majority of these
cases. In Asia, particularly China, smoking rates continue to
increase. Despite advances in therapy, the overall survival
rate for lung cancer patients remains only 15%. This poor
survival is probably due to the relatively advanced stage of
disease at diagnosis. To date, screening trials have had no
significant impact on survival [2]. Screening can detect
small (2–3 mm in size), asymptomatic nodules, but even
these nodules may already be malignant, and therefore late
in the course of the disease. Tumor cells have been found
in the peripheral blood and bone marrow of patients with
lung cancer of all sizes and stages [3,4].
If lung cancer could be identified earlier – at a preneoplas-
tic stage, before angiogenesis, invasion and micrometas-
tases can occur – we might have a greater chance of
improving survival. At this point, we have little information
about possible progenitor lesions. Which lesions are pre-
neoplastic? How and why do they progress? Is there any
treatment that can prevent progression? Advances in mo-
lecular biology and microdissection techniques, and great-
er understanding of genetic changes involved in malignant
transformation will aid in answering some of these ques-
tions. Advances in computerized tomography (CT), bron-
choscopy and genomics technology raise the possibility
that we may be able to detect these early lesions in vivo.
Therefore, if preneoplastic lesions can be defined, and if
appropriate therapies can be found, screening may then
significantly improve survival.
To define preneoplastic lesions, we need to understand the
molecular events that occur during bronchogenic carcino-
genesis. Carcinogenesis is thought to be a multistep proc-
ess consisting of the accumulation of gene mutations.
Preneoplastic lesions may be morphological phenotypes of
the different steps in this progression from normal to malig-
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nant tissue. We are just beginning to identify the presumed
preneoplastic lesions in the bronchial epithelium.
The World Health Organization (WHO) recently published
a tumor classification system that defines three different
preneoplastic lesions of the bronchial epithelium: squa-
mous dysplasia (SD) and carcinoma in situ (CIS), which
may be precursors to squamous cell carcinoma; atypical
adenomatous hyperplasia (AAH), which may be the pro-
genitor lesion for adenocarcinoma (particularly peripheral);
and diffuse idiopathic pulmonary neuroendocrine cell hy-
perplasia (DIP-NECH), which may progress to carcinoid
[5,6]. Additional possible preneoplastic lesions and condi-
tions include: basal cell hyperplasia and squamous meta-
plasia (progressing to SD and CIS); adenomatous
hyperplasia (progressing to AAH); angiogenic squamous
dysplasia (consisting of microscopic projections into the
bronchial lumen, surfaced by squamous dysplasia); and
pulmonary fibrosis.
No preneoplastic lesion has been clearly identified for small
cell carcinoma but, occasionally, SD/CIS can be seen in
the adjacent airway mucosa. However, mucosa that ap-
pears normal but with significant genetic abnormalities is
often found near small cell tumors, suggesting that these
tumors might arise without going through a stage of mor-
phologically recognizable preinvasive lesion [6].
In this review we will summarize the data supporting the
classification of these various lesions as preneoplastic, and
delve into some of the genetic changes found in AAH and
SD/CIS (the most extensively studied of these lesions).
Preneoplastic lesions
The sequence of precursor lesions for squamous cell car-
cinoma may be hyperplasia-metaplasia-dysplasia-CIS. This
progression of disease has long been recognized [7,8]. Ba-
sal cell hyperplasia is present when the basal cell layer is
more than three cells thick, and SD is present when there
is cytologic atypia. The WHO has classified SD and CIS as
preneoplastic lesions. This classification also provides cri-
teria for the distinction of mild, moderate, and severe dys-
plasia and CIS, based on the distribution of atypical cells
and mitotic figures (Fig. 1). Several problems occur with
this classification schema. The classification assumes that
the lesions progress in an orderly manner, from hyperplasia
to metaplasia, and then to increasing degrees of dysplasia,
but this may not be the case. In addition, the grading of le-
sions is not uniform. Some investigators and clinicians use
only two divisions – low grade versus high grade dysplasia.
There is also some overlap between categories, and in any
particular case a range of grades may be seen.
The sequence of precursor lesions for some pulmonary ad-
enocarcinomas may be adenomatous hyperplasia to AAH.
Recently, there has been great interest in AAH as the pre-
cursor for peripheral parenchymal adenocarcinoma, just as
colon adenomas are the precursors for colon adenocarci-
nomas [9]. Lesions in AAH are usually small, asymptomatic,
radiologically invisible, incidental microscopic findings in
surgically resected lung. Larger lesions may be grossly vis-
ible on the cut surface of the lung, or as ground glass le-
sions on a chest CT. Cuboidal or low columnar cells, with
the morphology of type 2 pneumocytes or Clara cells, line
a group of alveoli, and are sometimes distributed around a
terminal or respiratory bronchiole. Excess collagen and/or
lymphocytes might cause alveolar wall thickening. Mitotic
figures are unusual. Some lesions may have large amounts
of scar tissue or a heavy lymphoid infiltrate (Fig. 1).
At an almost indistinguishable point, the more atypical AAH
becomes a bronchoalveolar cell carcinoma (BAC) (in cur-
rent WHO classification, a noninvasive tumor growing by
replacement of alveolar lining cells). The largest and most
atypical AAH and BAC may actually be the same thing [6].
Larger AAH lesions may even have foci of invasion. Some
authors have therefore suggested using size (for example 5
mm) to distinguish between AAH and BAC. As in the squa-
mous cell carcinoma sequence, other problems with the
classification of AAH relate to reproducibility and uniformi-
ty, and lack of data about progression from hyperplasia to
mild, and then severe, atypical hyperplasia
Other possible preneoplastic conditions
A precursor lesion for carcinoid tumors may be DIP-NECH,
and some researchers have also suggested a possible re-
lationship with other neuroendocrine tumors. In DIP-NECH,
hyperplasia of airway neuroendocrine cells occurs without
invasion beyond the basement membrane, in association
with chronic inflammation or fibrosis in the lung. If the cells
extend into the interstitium and are associated with fibrous
tissue, the lesion is a carcinoid tumorlet (less than 5 mm) or
tumor (more than 5 mm). This condition is rare, so very little
data exists. Researchers have speculated that focal hyper-
plasia might provide a basis upon which neoplastic trans-
formation is more likely to occur.
Several diffuse, fibrosing conditions are associated with an
increased incidence of lung cancer, and may be consid-
ered preneoplastic conditions. Most recently, Hubbard and
colleagues found an approximately sevenfold increase in
the incidence of lung cancer in patients with idiopathic pul-
monary fibrosis, compared to age and sex-matched control
patients, even when controlled for smoking history [10]. In
fibrosis associated with pneumoconioses, such as asbes-
tosis or silicosis, it is unclear whether the tumor develop-
ment is related to the fibrosis or to the carcinogenic nature
of the exposure. The tumor development in diffuse pulmo-
nary fibrosis may be associated with AAH-like areas, con-Available online http://respiratory-research.com/content/3/1/20
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sisting of hyperplasia of alveolar lining cells, which may be
atypical.
Data supporting the preneoplastic nature of le-
sions
The data supporting the preneoplastic nature of these le-
sions is twofold, consisting of circumstantial evidence (le-
sions found in association with malignancies or in patients
with high risk of developing lung cancer) and genetic evi-
dence (genetic similarities found between tumors and their
associated preneoplastic lesions).
Circumstantial evidence
Patients with primary cancer in the lung or upper aerodi-
gestive tract have an increased risk of developing synchro-
nous or metachronous second primaries [11]. This risk is
likely to be related to chronic exposure of the bronchial tree
to carcinogens. Cigarette smoke causes a field change in
the mucosa with mutations demonstrable even in histolog-
ically normal areas ('field cancerization'). After smoking ces-
sation, many of these mutations seem to persist indefinitely,
so risk of lung cancer never reverts to that of a lifelong non-
smoker. Thus, broad areas of the tracheobronchial tree in
Figure 1
Normal bronchial mucosa, atypical adenomatous hyperplasia (AAH), squamous dysplasia and invasive squamous carcinoma have been stained for
various markers. The first column shows hematoxylin and eosin (H&E) tissue staining. The picture of AAH shows low (40× ) and high (400× , inset)
power images. The H&E staining of squamous dysplasia shows relatively normal mucosa on the left of the image and severe dysplasia on the right.
In severe dysplasia, there is considerable cellular pleiomorphism, coarse uneven chromatin, and little cell maturation. Vertical nuclei and mitotic fig-
ures are present in the lower two thirds of the mucosa. In invasive carcinoma the cytological aberration is extreme, mitoses occur at all levels of the
mucosa, and maturation is absent. The second column shows staining for the proliferation marker, Ki-67, in the various lesions. Ki-67 is essentially
negative in normal tissue. The images show increased Ki-67 in AAH, with a further increase in squamous dysplasia and carcinoma. In the third col-
umn, p53 is not observed in the normal bronchial mucosa or in AAH, but is increased in both squamous dysplasia and squamous carcinoma. In the
fourth column, p21 (p53-inducible cyclin dependent kinase inhibitor) is increased only in squamous carcinoma, but not in AAH or normal bronchial
mucosa.Respiratory Research   Vol 3 No 1   Greenberg et al.
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high-risk patients are prone to premalignant or multifocal
malignant change. The finding of these presumed premalig-
nant lesions in cancer-bearing lungs or in patients at high
risk of developing lung cancer is circumstantial evidence of
the lesions' preneoplastic nature, and supports the field
cancerization theory.
Several studies have shown an increased incidence of sq-
uamous metaplasia and dysplasia in the lungs of smokers.
In 1979, Auerbach and colleagues described a range of
histologic abnormalities in the lungs of smokers, from basal
cell hyperplasia to CIS. They found dysplasia in up to 40%
of heavy smokers [7,8]. In 1996, Agapitos and colleagues
showed that in an autopsy study of 531 people who died
of non-respiratory or non-cancer causes, the incidence of
squamous metaplasia and dysplasia increased sequentially
according to their degree of exposure to cigarette smoke
(nonsmokers, those exposed to secondary smoke, ex-
smokers and smokers) [12]. Angiogenic squamous dyspla-
sia has also been found in the airways of smokers before
the occurrence of invasive carcinoma [13].
In contrast, we still have little information about the inci-
dence of AAH or DIP/NECH in either smoking or nonsmok-
ing populations. Autopsy studies of AAH are hampered by
the presence of coincident pathology such as pneumonia,
pneumonitis, or fibrosis, which make AAH almost impossi-
ble to find. Most studies seem to show a relatively low inci-
dence of AAH in non-cancer-bearing lungs [14,15], and
DIP/NECH is an extremely rare lesion.
The increased incidence of squamous metaplasia and dys-
plasia, AAH, and DIP/NECH in lungs with the correspond-
ing tumors, is strong circumstantial evidence that these
lesions are preneoplastic. Squamous metaplasia, dyspla-
sia, and CIS are frequently found in association with inva-
sive cancer of all types [16]. It is more common to find AAH
in lungs with adenocarcinoma or large cell carcinoma. The
first descriptions of AAH in association with lung cancer
were made in the 1980s [9,17]. Overall figures for AAH in-
cidence range from 4.4 to 9.6% in lungs removed for be-
nign or metastatic disease, 3.3 to 11.1% in lungs resected
for squamous cell carcinoma, and 23.2 to 34.5% in lungs
resected for adenocarcinoma [15,18,19]. Zones of AAH
are sometimes seen around the tumor. Niho and colleagues
determined that, in seven patients with AAH and BAC, the
AAH lesions were all monoclonal, and in two cases the
BAC and contiguous AAH had identical monoclonality
[20]. These findings support the idea that the AAH-like
edge that is sometimes observed around a peripheral ade-
nocarcinoma is evidence of the pre-existing adenoma.
Many patients in these and other studies had multiple AAH
lesions and/or multiple synchronous primaries [18,21].
One patient was found to have 161 foci of AAH [22]. The
multifocal nature of AAH may explain the multicentricity that
is observed with some adenocarcinomas.
Essentially our only evidence that DIP/NECH is a preneo-
plastic lesion is circumstantial, based on lungs found to
have concurrent carcinoid tumors and DIP/NECH, and
most of the data comes from case studies [23,24]. The
finding of DIP/NECH may correlate with higher grade neu-
roendocrine malignancy. The relation between the hyper-
plasia and the tumor, if any, is not currently understood.
Genetic evidence
Alterations in gene expression and chromosome structure
known to be associated with malignant transformation can
be demonstrated in squamous metaplasia, dysplasia and
CIS, as well as in AAH. In this respect, DIP/NECH has not
been studied. The changes might be sequential, and their
frequency and number seem to increase with atypia in both
the metaplasia-dysplasia-CIS sequence and the AAH-ade-
nocarcinoma sequence. These changes can be seen both
as proof of the preneoplastic nature of the lesions, and as
possible markers of transformation (or imminent transfor-
mation). They may also become tools for early detection.
Cell proliferation markers and cell cycle regulators
Hyperproliferation and loss of cell cycle control seem to be
early events in malignant transformation. Several studies
have looked at different proliferation markers and cell cycle
regulators in preneoplastic lesions. Staining for prolifera-
tion markers (PCNA and Ki-67) increased with increasing
atypia in both squamous cell dysplasias and AAH [15,25].
Several studies have found the growth fraction in AAH is in-
termediate between normal lung tissue and adenocarcino-
ma [26,27].
Of the cell cycle regulators, P16 expression is lost in mod-
erate dysplasia, CIS, and squamous cell carcinoma, but its
loss is rare in AAH and adenocarcinoma. Cyclin D1 and E
are overexpressed in hyperplasia, metaplasia, dysplasia,
and CIS, as well as AAH, and increasing levels are seen
with increasing grade. Levels were, however, lower in BAC.
Loss of Rb (Retinoblastoma gene), which plays and impor-
tant role in cell cycle regulation during G0/G1, was not
seen in preinvasive lesions of either type [26,28,29].
DNA ploidy
Studies of the DNA content of cell nuclei, as a measure of
chromosomal gain or loss, are used to assess the degree
of nuclear aberration in a malignant cell population. Studies
in both squamous cell metaplasia/dysplasia and AAH have
shown progressive, increased aneuploidy with increasing
atypia [17,30,31]. Hirano and colleagues showed that, in
squamous metaplasia, 8% of low grade lesions and 33% of
high grade lesions were aneuploid [25]. In a study of AAH,
Nakanishi and colleagues demonstrated DNA aneuploidyAvailable online http://respiratory-research.com/content/3/1/20
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in none of the low grade AAH, 25% of high grade, and
34.6% of BAC [32]. A few studies have shown aneuploidy
of chromosome 7 in both the bronchial epithelium of pa-
tients with high risk for lung cancer (smokers, uranium min-
ers) and in preneoplastic lesions, with an increase in the
percentage of aneuploid cells from preinvasive to invasive
lesions [33,34].
p53 and the p53 transcription pathway
Abnormalities of p53 expression are frequent in lung carci-
noma, and many studies have found increased or abnormal
p53 in both the squamous metaplasia to dysplasia se-
quence, and AAH. Several studies in the squamous cell
carcinoma sequence have found an increase in stainable
p53, with increasingly severe dysplasia, ranging in various
studies from an average of 5% in low grade dysplasia to
60.4% in high grade dysplasia [25,28,29,35–38]. Studies
of p53 expression in AAH have yielded similar results,
showing increasing p53 expression with increasing atypia.
The overall levels, however, are somewhat lower in these
preneoplastic lesions indicating, perhaps, that p53 muta-
tion is a later event in peripheral adenocarcinogenesis than
in squamous carcinogenesis [15,39,40]. In contrast, the
studies have found no staining in normal epithelium, and
minimal staining in either metaplasia or adenomatous hy-
perplasia without atypia.
Other studies have looked at gene mutation instead of ex-
pression. These studies have shown that p53 gene muta-
tion in both AAH and bronchiolar epithelial dysplasia is
sometimes identical to, and sometimes different from, a
concurrent tumor [41–44]. In some studies the mutations
were seen with increasing frequency depending on the de-
gree of atypia [38,41]. Brambilla and colleagues found p53
expression in all cases of SD/CIS from cancer-bearing
lungs, but similar lesions from lungs with no cancer showed
no staining, suggesting that stabilization of p53 in the pre-
invasive lesion had a high predictive value for invasion [45].
Some authors have attempted to look at the interaction be-
tween the expression of p53 and that of other members of
the p53 signaling pathway. Hayashi and colleagues found
that in reactive lesions there is a correlation between p53
and p21 (p53-inducible cyclin dependent kinase inhibitor)
expression, and that this correlation is lost in both AAH and
carcinomas [46]. Their data suggest that p21 expression
may become p53 independent during transformation, even
at an early AAH stage. The protein MDM-2 binds to p53
and eliminates its ability to function as a transcription factor.
Alterations in MDM-2 expression have been found in prene-
oplastic lesions [47]. Other authors have found an appar-
ent deregulation of the p53 apoptosis transcription
pathway in precursor bronchial lesions of lung cancer. The
protein, Bcl-2, inhibits programmed cell death, and overex-
pression provides a survival advantage. This protein is over-
expressed in lung cancer (25% of squamous cell
carcinoma, 10% of adenocarcinoma, 64% of small cell car-
cinoma) [48,49]. Overexpression has also been seen in
preinvasive bronchial lesions, with some association with
increasing degree of dysplasia [28,37,50]. In one of these
studies, Bcl-2 overexpression was associated with Bax (an
inducer of apoptosis) downregulation in preinvasive lesions
and these changes were maintained during invasion [45].
Expressions of Bax, Bcl-2 and p21 did not correlate with
p53 status. The authors of this study concluded that Bax/
Bcl-2 imbalance contributes to clonal expansion during
premalignant states.
Telomerase
Telomerase is thought to play a role in conferring immortal-
ity on tumor cell populations. It may prevent progressive te-
lomere shortening and therefore cellular senescence. In
adult somatic cells telomerase is inactive, whereas the en-
zyme is activated and expressed in most human cancers.
Yashima and colleagues looked at telomerase expression
and activity in more than 200 preneoplastic and neoplastic
lesions from 40 patients: 34 with lung cancer; 5 with CIS;
and 1 without lung cancer [51]. They found telomerase ac-
tivity in 95–100% of CIS and invasive disease, in 70 to
80% of both hyperplastic and dysplastic bronchial epitheli-
um, and in only 20% of normal epithelium. When they as-
sayed activity, they found preinvasive lesions had enzyme
activity only 3–4 times normal, whereas in invasive disease,
activity was more than 40 times normal. Telomerase dereg-
ulation increased with increasing epithelial changes. In con-
trast, alveolar cells and AAH were negative for telomerase.
k-ras
The ras genes play an important role in signal transduction
and cellular proliferation (through the mitogen-activated
protein kinase pathways) and were among the first onco-
genes identified. Mutation of k-ras is found in about 30% of
non-small cell carcinoma, and is more common in adeno-
carcinoma than in squamous cell carcinoma. Accordingly,
studies have found k-ras mutation more commonly in AAH
than in SD. The AAH lesions often have different base
changes at codon 12 compared to the concurrent adeno-
carcinoma. This finding is consistent with the notion that
AAH represents field cancerization in the lung periphery
[52–54]. Several studies have found that parenchymal tu-
mors and AAH have k-ras mutation more frequently than
adenocarcinoma in the airways. This finding supports the
classification of adenocarcinomas into bronchial and pa-
renchymal subtypes, and suggests the importance of AAH
in development of parenchymal cancers. The bronchial
subtype might arise from bronchial epithelial dysplasia [55].
FHIT
The FHIT gene (fragile histidine triad tumor suppressor
gene) is frequently deleted in many carcinomas, includingRespiratory Research   Vol 3 No 1   Greenberg et al.
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lung. The gene covers a genomic region at 3p14.2, which
spans the most active of the common human chromosomal
fragile regions FRA3B. These fragile sites might be espe-
cially susceptible to carcinogen damage. The FHIT gene
encodes a protein that hydrolyzes diadenosine triphos-
phate to ADP and AMP in vitro. Although the in vivo func-
tion of this protein is not known, it may play a role in cell
death through apoptosis and/or may affect cell prolifera-
tion. Loss of FHIT protein is the most frequent alteration in
non-small cell lung carcinoma and precancerous lesions
(both squamous cell and adenocarcinoma). The frequency
of loss increases as the grade of dysplasia increases [56].
In some studies, loss of FHIT protein expression was al-
most universal by the severe SD/CIS stage. This loss is sig-
nificantly more frequent in tumors and preneoplastic
lesions of smokers (75%) than of nonsmokers (39%), and
is an independent and more frequent event than p53 over-
expression. It is more common in squamous cell carcinoma
(87%) than in adenocarcinoma (57%) [57–60]. Loss of
FHIT protein expression is also common in small cell carci-
nomas and neuroendocrine lung tumors. In one study, loss
of heterozygosity (LOH) at this locus was found in atypical
carcinoids as well [61].
Genomic alterations and LOH studies
Several chromosomal sites are most frequently involved in
lung cancer. The most common and earliest changes in
both squamous cell carcinoma and adenocarcinoma seem
to involve allele-specific loss of genome at 3p and 9p and
perhaps 17q, among others [22,43]. These changes in-
volve all regions of the respiratory tract, and occur with in-
creasing frequency with increasing atypia [41,43,44,62–
66]. Some of these changes have also been seen in the
normal appearing bronchial epithelium of chronic smokers
[67–69]. Studies suggest that these deletions occur more
frequently in squamous metaplasia/dysplasia than in AAH,
suggesting they may be a later event in adenocarcinoma
pathogenesis [41].
In some of the most extensive studies to date, Wistuba and
colleagues looked at LOH at 10 chromosomal regions fre-
quently deleted in lung cancer [68,70]. In one study they
examined normal tissue, SD, CIS, and invasive tumors from
12 patients with lung cancer. In a subsequent study they
looked at 97 lung cancers and 54 preneoplastic lesions
from patients without lung cancer. At one or more regions
LOH was common in normal-appearing mucosa, but they
found a progressive increase in overall LOH frequency and
size, along with increasingly severe histopathological
changes, in both lungs with lung cancer and those without.
In CIS and invasive squamous cell carcinoma, 3p allele loss
was almost universal. The earliest and most frequent re-
gions of loss were at 3p21, 22–24, 25 and 9p21. Losses
at 3p14.2, 14–21 began to appear in the hyperplastic/
metaplastic lesions. Loss of p53 and Rb loci was present
in more advanced lesions. The same allele was lost in 90%
of corresponding preneoplastic and invasive lesions. The
authors hypothesized that many sequentially occurring, al-
lele-specific changes begin in independent foci of the bron-
chial epithelium, early in the pathogenesis of squamous cell
carcinoma.
Overall, the data seem to show that localized, specific LOH
of 3p and 9p occurs very early in the evolution of preinva-
sive disease of the bronchial epithelium. This is seen even
in phenotypically normal or hyperplasic epithelium. As the
lesions advance, more 3p deletions including 14.2 begin to
appear, as does 17p LOH, and perhaps other regional de-
letions. By the time the stage of severe SD/CIS is reached,
there is extensive loss of 3p and persistent loss of the 9p
and 17p regions.
Methylation
Recently, there has been increased interest in the signifi-
cance of the methylation of genes and their promoters. Ab-
errant methylation of gene promoters can silence gene
expression. In an animal model exposed to tobacco carcin-
ogen, methylation was frequent in preneoplastic lesions
[71]. In human lung cancer, p16, p53 and k-ras promoter
hypermethylation has been seen. Aberrant methylation of
the promoter regions of other tumor suppressors may also
play a role in carcinogenesis. A few studies have begun to
look at methylation patterns in preneoplastic lesions. Until
now, p16 tumor suppressor gene promoter methylation has
been the most studied [72]. Belinsky and colleagues found
that the frequency of methylation increased during progres-
sion from basal cell hyperplasia to squamous metaplasia to
SD/CIS [71]. Zochbauer-Muller et al. looked at promoter
methylation of multiple genes, and found that methylation
was common in the promoter region of multiple genes in
both tumors and associated, nonmalignant tissues [73].
Other possible markers of transformation
Vascular growth is an important aspect of malignant trans-
formation. Increasing neovascularization and vascular
count has been found with increasing dysplasia of lesions
of the bronchial tree [74]. Accordingly, expression of vas-
cular endothelial growth factor was found to increase from
normal tissue to SD to CIS to invasive cancer [75]. Chang-
es in the extracellular matrix may also distinguish normal,
preinvasive, and malignant lesions. One study found in-
creased matrix disarrangement of the basement membrane
zone with increasing degree of neoplasia [76].
Many other proteins have been found to have either in-
creased or decreased expression, correlating with increas-
ing histopathologic abnormality. In the metaplasia-
dysplasia-squamous cell carcinoma sequence, some of the
proteins that may have increased expression include hy-
aluronan [76], epidermal growth factor receptor [36], cal-Available online http://respiratory-research.com/content/3/1/20
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cyclin [77], fatty acid synthase [78], thrombomodulin [79],
and epithelial cellular adhesion molecule (17-1A) [80]. In
the AAH-adenocarcinoma sequence, some of the proteins
with increased expression include carcinoembryonic anti-
gen [81], surfactant apoprotein A [81] (although one study
[82] found that surfactant apoprotein A seemed to de-
crease as the lesions advanced), cytochrome p450 [81], c-
erbB2 (product of the neu oncogene) [39], and cyclooxy-
genase 2 [83,84].
Many other potential markers have not yet been investigat-
ed in preneoplastic lesions, but they are abnormally ex-
pressed in lung cancer. Expression of Hif1α  is increased in
most types of malignancy, including lung [85]. A tumor sup-
pressor gene, Rb-related gene pRb2/p130, may play a role
in lung cancer development [86]. Expression of the 14-3-3
family of proteins is increased in lung cancer tissues [87].
Another potential marker is HnRNPB1, a protein that is
found in 100% of squamous cell carcinoma of the lung, and
expression in the sputum has been correlated with risk of
lung cancer development in certain populations [88,89].
The presence of DNA adducts may also potentially identify
preneoplastic lesions [90].
Clinical studies of lesions and risks of progression
The cause and effect relationship between these various
genetic abnormalities and morphologic changes is un-
known. Given the relationship between many of these find-
ing and the grades of atypia, abnormal gene expression
might be responsible for the changes in morphology. The
phenotype/histology, however, is reversible in some cases.
Very few clinical studies have looked at the outcome of pre-
neoplastic lesions. Based on studies of epithelial dysplasia
in sputum samples, it might take up to 10 years for invasion
to occur [91]. Some studies have shown that when atypia
is seen in the sputum, it may take 6–36 months for a lesion
to be visible bronchoscopically [6]. In a study of patients
who underwent fluorescence bronchoscopy at regular in-
tervals for at least six months, progression to invasive can-
cer occurred in 5/9 patients with CIS. Neoplastic lesions
were detected at other sites in 4/9 patients [92]. Ponticello
and colleagues followed a group of smokers without lung
cancer for four years. Initially, 22 bronchial dysplastic le-
sions were detected. Ten lung cancers developed during
follow up, seven of which developed in lesions that had ex-
pressed p53. The authors suggested that p53 immunohis-
tochemistry can identify the bronchial preneoplastic lesions
that will progress to lung cancer [93].
It is almost impossible to follow AAH in a longitudinal study,
since the lesions are generally only identified incidentally in
lung resected for other reasons. It has been found that, in
patients who have had resections for adenocarcinoma, the
concurrent presence of AAH does not appear to affect sur-
vival [19,94]. In one study the concurrent presence of AAH
actually seemed to be a favorable prognostic indicator [95].
The fate of DIP/NECH is also unknown.
Conclusion
Although great strides have been made in the last decade
in describing the sequence of lung carcinogenesis, we
need much more information to effectively intervene in this
process. Studies in the last few years have clearly shown
that there is an accumulation of various genetic abnormali-
ties, which correlate with increasing morphologic changes,
in both the squamous cell carcinoma and adenocarcinoma
sequence. Very little is known so far about the details of
carcinoid/neuroendocrine or small cell carcinoma develop-
ment. Changes in the p53 gene and 3p LOH have been the
most extensively studied mutations, however there are
many other potential markers. We do not know which ge-
netic changes are most important, or at what stage the
process is irreversible. It is likely that several different com-
binations of abnormalities can cause transformation. Im-
provements in CT technology may allow us to detect AAH
in vivo, and advances in bronchoscopy, including fluores-
cence bronchoscopy, may aid in the detection of preneo-
plastic central bronchial lesions (although to date, the
specificity is relatively low). Even if we are able to detect the
histologic preneoplastic lesions, however, we still do not
know the risk of progression. The histologic lesions may be
reversible if carcinogen exposure ceases, although the ge-
nomic alterations do not regress. Therefore, if we are to af-
fect lung cancer mortality, it is important to identify the
genetic lesions that predispose to malignant transformation
so that these can be detected along with the more variable
histologic changes. Just as importantly, there is a need to
develop a means to prevent this transformation. In this re-
view we have summarized the available information on ge-
netic and biochemical changes in presumed preneoplastic
lesions of the bronchial epithelium. This review thus pro-
vides a basis for further investigations in this area.
Abbreviations
AAH = atypical adenomatous hyperplasia; BAC = bronchoalveolar cell 
carcinoma; CIS = carcinoma in situ; CT = computerized tomography; 
DIP-NECH = diffuse idiopathic pulmonary neuroendocrine cell hyper-
plasia; LOH = loss of heterozygosity; SD = squamous dysplasia; WHO 
= World Health Organization.
References
1. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM: Molecular
and genetic aspects of lung cancer. Am J Respir Crit Care Med
2000, 161:1355-1367
2. Patz EF Jr, Goodman PC, Bepler G: Screening for lung cancer.
N Engl J Med 2000, 343:1627-1633
3. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW, Yang PC: Detec-
tion and quantitation of circulating cancer cells in the periph-
eral blood of lung cancer patients. Cancer Res 1998, 58:2761-
2765
4. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter
O, Riethmuller G: Frequency and prognostic significance of iso-
lated tumour cells in bone marrow of patients with non-small-
cell lung cancer without overt metastases.  Lancet 1996,
347:649-653Respiratory Research   Vol 3 No 1   Greenberg et al.
Page 8 of 10
(page number not for citation purposes)
5. Travis CT WD, Corrin B, in collaboration with pathologists from 14
countries: Histological typing of lung and pleural tumours. In
World Health Organization International Histological Classifica-
tion of Tumours. 1999
6. Kerr KM: Pulmonary preinvasive neoplasia. J Clin Pathol 2001,
54:257-271
7. Auerbach O, Hammond EC, Garfinkel L: Changes in bronchial
epithelium in relation to cigarette smoking, 1955–1960 vs
1970–1977. N Engl J Med 1979, 300:381-385
8. Auerbach O, Stout AP, Hammond EC, Garfinkel L: Changes in
bronchial epithelium in relation to sex, age, residence, smok-
ing and pneumonia. Nord Hyg Tidskr 1962, 267:111-119
9. Miller RR, Nelems B, Evans KG, Muller NL, Ostrow DN: Glandular
neoplasia of the lung. A proposed analogy to colonic tumors.
Cancer 1988, 61:1009-1014
10. Fraire AE, Greenberg SD: Carcinoma and diffuse interstitial fi-
brosis of lung. Cancer 1973, 31:1078-1086
11. Franklin WA: Diagnosis of lung cancer: pathology of invasive
and preinvasive neoplasia. Chest 2000, 117:80S-89S
12. Agapitos E, Mollo F, Tomatis L, Katsouyanni K, Lipworth L, Delsed-
ime L, Kalandidi A, Karakatsani A, Riboli E, Saracci R, Trichopoulos
D: Epithelial, possibly precancerous, lesions of the lung in re-
lation to smoking, passive smoking, and socio-demographic
variables. Scand J Soc Med 1996, 24:259-263
13. Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC,
Kennedy TC, Prindiville S, Franklin WA: Angiogenic squamous
dysplasia in bronchi of individuals at high risk for lung cancer.
Clin Cancer Res 2000, 6:1616-1625
14. Sterner DJ, Mori M, Roggli VL, Fraire AE: Prevalence of pulmo-
nary atypical alveolar cell hyperplasia in an autopsy popula-
tion: a study of 100 cases. Mod Pathol 1997, 10:469-473
15. Yokose T, Ito Y, Ochiai A: High prevalence of atypical adenom-
atous hyperplasia of the lung in autopsy specimens from eld-
erly patients with malignant neoplasms. Lung Cancer 2000,
29:125-130
16. Auerbach O, Saccomanno G, Kuschner M, Brown RD, Garfinkel L:
Histologic findings in the tracheobronchial tree of uranium
miners and non-miners with lung cancer.  Cancer 1978,
42:483-489
17. Kodama T, Biyajima S, Watanabe S, Shimosato Y: Morphometric
study of adenocarcinomas and hyperplastic epithelial lesions
in the peripheral lung. Am J Clin Pathol 1986, 85:146-151
18. Weng SY, Tsuchiya E, Kasuga T, Sugano H: Incidence of atypical
bronchioloalveolar cell hyperplasia of the lung: relation to his-
tological subtypes of lung cancer. Virchows Arch A Pathol Anat
Histopathol 1992, 420:463-471
19. Chapman AD, Kerr KM: The association between atypical ade-
nomatous hyperplasia and primary lung cancer. Br J Cancer
2000, 83:632-636
20. Niho S, Yokose T, Suzuki K, Kodama T, Nishiwaki Y, Mukai K: Mon-
oclonality of atypical adenomatous hyperplasia of the lung. Am
J Pathol 1999, 154:249-254
21. Dohmoto K, Fujita J, Ohtsuki Y, Kotsuna N, Mitsunaka H, Kuwabara
H, Takahara J: Synchronous four primary lung adenocarcinoma
associated with multiple atypical adenomatous hyperplasia.
Lung Cancer 2000, 27:125-130
22. Anami Y, Matsuno Y, Yamada T, Takeuchi T, Nakayama H, Hiro-
hashi S, Noguchi M: A case of double primary adenocarcinoma
of the lung with multiple atypical adenomatous hyperplasia.
Pathol Int 1998, 48:634-640
23. Miller RR, Muller NL: Neuroendocrine cell hyperplasia and oblit-
erative bronchiolitis in patients with peripheral carcinoid tu-
mors. Am J Surg Pathol 1995, 19:653-658
24. Aguayo SM, Miller YE, Waldron JA Jr, Bogin RM, Sunday ME, Sta-
ton GW Jr, Beam WR, King TE Jr: Brief report: idiopathic diffuse
hyperplasia of pulmonary neuroendocrine cells and airways
disease. N Engl J Med 1992, 327:1285-1288
25. Hirano T, Franzen B, Kato H, Ebihara Y, Auer G: Genesis of squa-
mous cell lung carcinoma. Sequential changes of proliferation,
DNA ploidy, and p53 expression. Am J Pathol 1994, 144:296-
302
26. Kurasono Y, Ito T, Kameda Y, Nakamura N, Kitamura H: Expres-
sion of cyclin D1, retinoblastoma gene protein, and p16 MTS1
protein in atypical adenomatous hyperplasia and adenocarci-
noma of the lung. An immunohistochemical analysis. Virchows
Arch 1998, 432:207-215
27. Carey FA, Wallace WAH, Fergusson RJ, Kerr KM, Lamb D: Alve-
olar atypical hyperplasia in association with primary pulmo-
nary adenocarcinoma: a clinicopathological study of 10 cases.
Thorax 1992, 47:1041-1043
28. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla
C: Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in prein-
vasive bronchial lesions. Clin Cancer Res 1999, 5:243-250
29. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS:
Overexpression of cyclins D1 and E is frequent in bronchial
preneoplasia and precedes squamous cell carcinoma devel-
opment. Cancer Res 1999, 59:2470-2476
30. Smith AL, Hung J, Walker L, Rogers TE, Vuitch F, Lee E, Gazdar
AF: Extensive areas of aneuploidy are present in the respirato-
ry epithelium of lung cancer patients.  Br J Cancer 1996,
73:203-209
31. Mori M, Chiba R, Takahashi T: Atypical adenomatous hyperpla-
sia of the lung and its differentiation from adenocarcinoma.
Characterization of atypical cells by morphometry and multi-
variate cluster analysis. Cancer 1993, 72:2331-2340
32. Nakanishi K, Hiroi S, Kawai T, Suzuki M, Torikata C: Argyrophilic
nucleolar-organizer region counts and DNA status in bronchi-
oloalveolar epithelial hyperplasia and adenocarcinoma of the
lung. Hum Pathol 1998, 29:235-239
33. Zojer N, Dekan G, Ackermann J, Fiegl M, Kaufmann H, Drach J, Hu-
ber H: Aneuploidy of chromosome 7 can be detected in inva-
sive lung cancer and associated premalignant lesions of the
lung by fluorescence in situ hybridisation. Lung Cancer 2000,
28:225-235
34. Lechner JF, Neft RE, Gilliland FD, Crowell RE, Belinsky SA: Molec-
ular identification of individuals at high risk for lung cancer. Ra-
diat Oncol Invest 1997, 5:103-105
35. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane
DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR: p53 protein ac-
cumulates frequently in earlybronchial neoplasia. Cancer Res
1993, 53:4817-4822
36. Rusch V, Klimstra D, Linkov I, Dmitrovsky E: Aberrant expression
of p53 or the epidermal growth factor receptor is frequent in
early bronchial neoplasia and coexpression precedes squa-
mous cell carcinoma development. Cancer Res 1995, 55:1365-
1372
37. Katabami M, Dosaka-Akita H, Honma K, Kimura K, Fujino M, Uch-
ida Y, Mikami H, Ohsaki Y, Kawakami Y, Kikuchi K: p53 and Bcl-2
expression in pneumoconiosis-related pre-cancerous lesions
and lung cancers: frequent and preferential p53 expression in
pneumoconiotic bronchiolar dysplasias.  Int J Cancer 1998,
75:504-511
38. Chyczewski L, Chyczewska E, Niklinski J, Niklinska W, Sulkowska
M, Naumnik W, Kovalchuk O: Morphological and molecular as-
pects of cancerogenesis in the lung. Folia Histochem Cytobiol
2001, 39:149-152
39. Kerr KM, Carey FA, King G, Lamb D: Atypical alveolar hyperpla-
sia: relationship with pulmonary adenocarcinoma, p53, and c-
erbB-2 expression. J Pathol 1994, 174:249-256
40. Slebos RJ, Baas IO, Clement MJ, Offerhaus GJ, Askin FB, Hruban
RH, Westra WH: p53 alterations in atypical alveolar hyperpla-
sia of the human lung. Hum Pathol 1998, 29:801-808
41. Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H: p53
mutation and allelic loss of chromosome 3p, 9p of preneoplas-
tic lesions in patients with nonsmall cell lung carcinoma. Can-
cer 1999, 85:341-347
42. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen
NM, Rabbitts P: p53 and chromosome 3 abnormalities, charac-
teristic of malignant lung tumours, are detectable in preinva-
sive lesions of the bronchus. Oncogene 1992, 7:1989-1997
43. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U,
Della Porta G, Pierotti MA: Deletions of 17p and p53 mutations
in preneoplastic lesions of the lung.  Cancer Res 1992,
52:6079-6082
44. Nishisaka T, Takeshima Y, Inai K: Evaluation of p53 gene muta-
tion and loss of heterozygosity of 3p, 9p and 17p in precancer-
ous lesions of 29 lung cancer patients. Hiroshima J Med Sci
2000, 49:109-116
45. Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A,
Brambilla C: p53 mutant immunophenotype and deregulation
of p53 transcription pathway (Bcl2, Bax, and Waf1) in precur-
sor bronchial lesions of lung cancer. Clin Cancer Res 1998,
4:1609-1618Available online http://respiratory-research.com/content/3/1/20
Page 9 of 10
(page number not for citation purposes)
46. Hayashi H, Miyamoto H, Ito T, Kameda Y, Nakamura N, Kubota Y,
Kitamura H: Analysis of p21Waf1/Cip1 expression in normal,
premalignant, and malignant cells during the development of
human lung adenocarcinoma. Am J Pathol 1997, 151:461-470
47. Rasidakis A, Orphanidou D, Kalomenidis J, Papamichalis G, Tou-
mbis M, Lambaditis J, Sacharidou A, Papastamatiou H, Jorda-
noglou J: Expression of mdm-2 protein in neoplastic,
preneoplastic, and normal bronchial mucosa specimens: com-
parative study with p53 expression. Hybridoma 1998, 17:339-
345
48. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB,
Harris A, Gatter KC, Mason DY: bcl-2 protein in non-small-cell
lung carcinoma. N Engl J Med 1993, 329:690-694
49. Kennedy MM, Lamb D, King G, Kerr KM: Cell proliferation, cell
loss and expression of bcl-2 and p53 in human pulmonary ne-
oplasms. Br J Cancer 1997, 75:545-547
50. Walker C, Robertson L, Myskow M, Dixon G: Expression of the
BCL-2 protein in normal and dysplastic bronchial epithelium
and in lung carcinomas. Br J Cancer 1995, 72:164-169
51. Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milch-
grub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF: Telom-
erase expression in respiratory epithelium during the
multistage pathogenesis of lung carcinomas.  Cancer Res
1997, 57:2373-2377
52. Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF: K-ras mu-
tations are a relatively late event in the pathogenesis of lung
carcinomas. Cancer Res 1994, 54:5811-5815
53. Sagawa M, Saito Y, Fujimura S, Linnoila RI: K-ras point mutation
occurs in the early stage of carcinogenesis in lung cancer. Br
J Cancer 1998, 77:720-723
54. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus
GJ, Slebos RJ: K-ras oncogene activation in atypical alveolar
hyperplasias of the human lung. Cancer Res 1996, 56:2224-
2228
55. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH: The
pattern of K-ras mutation in pulmonary adenocarcinoma de-
fines a new pathway of tumour development in the human
lung. J Pathol 1997, 181:401-404
56. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli
C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S:
Loss of FHIT function in lung cancer and preinvasive bronchial
lesions. Cancer Res 1998, 58:5032-5037
57. Huebner K, Druck T, Siprashvili Z, Croce CM, Kovatich A, McCue
PA: The role of deletions at the FRA3B/FHIT locus in carcino-
genesis. Recent Results Cancer Res 1998, 154:200-215
58. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader
SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone
G, Gazdar AF, Minna JD: FHIT and FRA3B 3p14.2 allele loss are
common in lung cancer and preneoplastic bronchial lesions
and are associated with cancer-related FHIT cDNA splicing ab-
errations. Cancer Res 1997, 57:2256-2267
59. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D,
Hong WK, Mao L: Loss of Fhit is frequent in stage I non-small
cell lung cancer and in the lungs of chronic smokers. Cancer
Res 1999, 59:4798-4803
60. Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttitta F,
Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M,
Chella A, Angeletti CA, Pastorino U, Huebner K, Bevilaqua G, Pi-
lotti S, Croce CM, Pierotti MA: Association between cigarette
smoking and FHIT gene alterations in lung cancer. Cancer Res
1997, 57:2121-2123
61. Kovatich A, Friedland DM, Druck T, Hadaczek P, Huebner K,
Comis RL, Hauck W, McCue PA: Molecular alterations to hu-
man chromosome 3p loci in neuroendocrine lung tumors.
Cancer 1998, 83:1109-1117
62. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD,
Gazdar AF: Allele-specific chromosome 3p deletions occur at
an early stage in the pathogenesis of lung carcinoma. JAMA
1995, 273:1908
63. Endo C, Sagawa M, Sato M, Chen Y, Sakurada A, Aikawa H, Taka-
hashi S, Usuda K, Saito Y, Fujimura S: Sequential loss of heter-
ozygosity in the progression of squamous cell carcinoma of
the lung. Br J Cancer 1998, 78:612-615
64. Yamasaki M, Takeshima Y, Fujii S, Kitaguchi S, Matsuura M,
Tagawa K, Inai K: Correlation between genetic alterations and
histopathological subtypes in bronchiolo-alveolar carcinoma
and atypical adenomatous hyperplasia of the lung. Pathol Int
2000, 50:778-785
65. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD,
Gazdar AF: Allele-specific loss in chromosome 9p loci in pre-
neoplastic lesions accompanying non-small cell lung cancers.
J Natl Cancer Inst 1995, 87:1224-1229
66. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts
PH: Sequential molecular genetic changes in lung cancer de-
velopment. Oncogene 1995, 11:2591-2598
67. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J,
Samet JM, Srivastava S, Minna JD, Gazdar AF: Molecular damage
in the bronchial epithelium of current and former smokers. J
Natl Cancer Inst 1997, 89:1366-1373
68. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L,
Fondon JW 3rd, Garner HR, McKay B, Latif F, Lerman MI, Lam S,
Gazdar AF, Minna JD: High resolution chromosome 3p allelo-
typing of human lung cancer and preneoplastic/preinvasive
bronchial epithelium reveals multiple, discontinuous sites of
3p allele loss and three regions of frequent breakpoints. Can-
cer Res 2000, 60:1949-1960
69. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Brox-
son A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman
WN, Hong WK: Clonal genetic alterations in the lungs of cur-
rent and former smokers. J Natl Cancer Inst 1997, 89:857-862
70. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD,
Gazdar AF: Sequential molecular abnormalities are involved in
the multistage development of squamous cell lung carcinoma.
Oncogene 1999, 18:643-650
71. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G,
Gabrielson E, Baylin SB, Herman JG: Aberrant methylation of
p16(INK4a) is an early event in lung cancer and a potential bi-
omarker for early diagnosis. Proc Natl Acad Sci USA 1998,
95:11891-11896
72. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ
detection of the hypermethylation-induced inactivation of the
p16 gene as an early event in oncogenesis. Proc Natl Acad Sci
USA 1999, 96:12754-12759
73. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF,
Minna JD: Aberrant promoter methylation of multiple genes in
non-small cell lung cancers. Cancer Res 2001, 61:249-255
74. Fisseler-Eckhoff A, Rothstein D, Muller KM: Neovascularization in
hyperplastic, metaplastic and potentially preneoplastic lesions
of the bronchial mucosa. Virchows Arch 1996, 429:95-100
75. Fontanini G, Calcinai A, Boldrini L, Lucchi M, Mussi A, Angeletti
CA, Cagno C, Tognetti MA, Basolo F: Modulation of neoangio-
genesis in bronchial preneoplastic lesions. Oncol Rep 1999,
6:813-817
76. Fisseler-Eckhoff A, Prebeg M, Voss B, Muller KM: Extracellular
matrix in preneoplastic lesions and early cancer of the lung.
Pathol Res Pract 1990, 186:95-101
77. Kayser K, Andre S, Bovin NV, Zeng FY, Gabius HJ: Preneoplasia-
associated expression of calcyclin and of binding sites for syn-
thetic blood group A/H trisaccharide – exposing neoglycocon-
jugates in human lung. Cancer Biochem Biophys 1997, 15:235-
243
78. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger
DC, Grizzle WE: The expression of fatty acid synthase (FASE)
is an early event in the development and progression of squa-
mous cell carcinoma of the lung. Hum Pathol 2000, 31:1068-
1073
79. Tolnay E, Wiethege T, Muller KM: Expression and localization of
thrombomodulin in preneoplastic bronchial lesions and in
lung cancer. Virchows Arch 1997, 430:209-212
80. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Griz-
zle WE: The expression of Ep-CAM (17-1A) in squamous cell
cancers of the lung. Hum Pathol 2000, 31:482-487
81. Mori M, Tezuka F, Chiba R, Funae Y, Watanabe M, Nukiwa T, Taka-
hashi T: Atypical adenomatous hyperplasia and adenocarcino-
ma of the human lung: their heterology in form and analogy in
immunohistochemical characteristics.  Cancer 1996, 77:665-
674
82. Kitamura H, Kameda Y, Ito T, Hayashi H, Nakamura N, Nakatani Y,
Inayama Y, Kanisawa M: Cytodifferentiation of atypical adenom-
atous hyperplasia and bronchioloalveolar lung carcinoma: im-
munohistochemical and ultrastructural studies. Virchows Arch
1997, 431:415-424Respiratory Research   Vol 3 No 1   Greenberg et al.
Page 10 of 10
(page number not for citation purposes)
83. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y,
Ochiai A: Increased cyclooxygenase 2 (COX-2) expression oc-
curs frequently in precursor lesions of human adenocarcino-
ma of the lung. Lung Cancer 2000, 30:73-81
84. Wardlaw SA, March TH, Belinsky SA: Cyclooxygenase-2 expres-
sion is abundant in alveolar type II cells in lung cancer-sensi-
tive mouse strains and in premalignant lesions.
Carcinogenesis 2000, 21:1371-1377
85. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D,
Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpres-
sion of hypoxia-inducible factor 1alpha in common human
cancers and their metastases.  Cancer Res 1999, 59:5830-
5835
86. Claudio PP, Caputi M, Giordano A: The RB2/p130 gene: the lat-
est weapon in the war against lung cancer? Clin Cancer Res
2000, 6:754-764
87. Nakanishi K, Hashizume S, Kato M, Honjoh T, Setoguchi Y, Yas-
umoto K: Elevated expression levels of the 14-3-3 family of
proteins in lung cancer tissues. Hum Antibodies 1997, 8:189-
194
88. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK,
Ruckdeschel JC, Taylor PR, Zhukov T, Zhou WH, Qiao YL, Yao
SX: Prospective detection of preclinical lung cancer: results
from two studies of heterogeneous nuclear ribonucleoprotein
A2/B1 overexpression. Clin Cancer Res 1997, 3:2237-2246
89. Qiao YL, Tockman MS, Li L, Erozan YS, Yao SX, Barrett MJ, Zhou
WH, Giffen CA, Luo XC, Taylor PR: A case-cohort study of an
early biomarker of lung cancer in a screening cohort of Yunnan
tin miners in China. Cancer Epidemiol Biomarkers Prev 1997,
6:893-900
90. De Flora S, Balansky R, Scatolini L, Di Marco C, Gasparini L, Or-
lando M, Izzotti A: Adducts to nuclear DNA and mitochondrial
DNA as biomarkers in chemoprevention. IARC Sci Publ 1996,
139:291-301
91. Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan
LM: Development of carcinoma of the lung as reflected in ex-
foliated cells. Cancer 1974, 33:256-270
92. Venmans BJ, van Boxem TJ, Smit EF, Postmus PE, Sutedja TG:
Outcome of bronchial carcinoma in situ.  Chest 2000,
117:1572-1576
93. Ponticiello A, Barra E, Giani U, Bocchino M, Sanduzzi A: P53 im-
munohistochemistry can identify bronchial dysplastic lesions
proceeding to lung cancer: a prospective study. Eur Respir J
2000, 15:547-552
94. Suzuki K, Nagai K, Yoshida J, Yokose T, Kodama T, Takahashi K,
Nishimura M, Kawasaki H, Yokozaki M, Nishiwaki Y: The progno-
sis of resected lung carcinoma associated with atypical ade-
nomatous hyperplasia: a comparison of the prognosis of well-
differentiated adenocarcinoma associated with atypical ade-
nomatous hyperplasia and intrapulmonary metastasis. Cancer
1997, 79:1521-1526
95. Takigawa N, Segawa Y, Nakata M, Saeki H, Mandai K, Kishino D,
Shimono M, Ida M, Eguchi K: Clinical investigation of atypical
adenomatous hyperplasia of the lung.  Lung Cancer 1999,
25:115-121